MedWatch

Major boost for Genmab’s candidate drug

US medicines authorities, FDA, have awarded the coveted breakthrough designation to a candidate drug from Danish biotech Genmab. It could lead to an accelerated market entrance for the drug and had an immediate effect on the company share.

Foto: Genmab / PR

The good news keep on coming for Danish biotech Genmab.

The company - whose share has gone up by 85 % this year and is currently picking up even more speed - has received a giant boost for a drug being developed against a certain type of cancer of the blood known as myelomatosis: The FDA has awarded it breakthrough status in the US, the company reveals in a stock market release Wednesday.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier